Development of a unified clinical trial database for Alzheimer's disease

Alzheimer's and Dementia

Volumn 11, Issue 10, 2015, Pages 1212-1221

  Neville, Jon ^a   Kopko, Steve ^b   Broadbent, Steve ^a   Avilés, Enrique ^a   Stafford, Robert ^a   Solinsky, Christine M ^c   Bain, Lisa J ^d   Cisneroz, Martin ^a   Romero, Klaus ^a   Stephenson, Diane ^a  

^a CRITICAL PATH INSTITUTE   (United States)

^b Clinical Data Interchange Standards Consortium   (United States)

^c USC Department of Pharmaceutical Sciences   (United States)

^d Independent Science Writer   (United States)

Author keywords

Alzheimer's disease; Clinical trials database; Data integration; Data standardization; Facilitated access; Placebo data

Indexed keywords

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; DATA BASE; DISEASE COURSE; DISEASE SEVERITY; HEALTH CARE ORGANIZATION; HUMAN; MENTAL DETERIORATION; META ANALYSIS (TOPIC); MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMULATION; STANDARDIZATION; CLINICAL TRIAL (TOPIC); COGNITION; DECISION MAKING; FACTUAL DATABASE; INTERNET; STANDARD; STATISTICS;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; COGNITION; DATABASES, FACTUAL; DECISION MAKING; HUMANS; INTERNET; REFERENCE STANDARDS; STATISTICS AS TOPIC;

EID: 84945453845     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2014.11.005     Document Type: Article

References (34)

1. Alzheimer's Disease International. World Alzheimer's report. 2009.
2. S. Olson, and A.S. Downey Sharing clinical research data: workshop summary 2013 Institute of Medicine of the National Academies Washington, D.C
3. Food and Drug Administration. Innovation or stagnation: challenges and opportunity on the critical path to new medical products. 2004. Available at: http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm. Accessed February 26, 2013.
4. K. Romero, B. Corrigan, J. Neville, S. Kopko, and M. Cantillon Striving for an integrated drug development process for neurodegeneration: the coalition against major diseases Neurodegen Dis Manage 1 2011 1 7
5. K. Romero, M. de Mars, D. Frank, M. Anthony, J. Neville, L. Kirby, and et al. The coalition against major diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases Clin Pharmacol Ther 86 2009 365 367
6. M.W. Weiner, D.P. Veitch, P.S. Aisen, L.A. Beckett, N.J. Cairns, R.C. Green, and et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement 9 2013 e111 e194
7. Clinical Data Interchange Standards Consortium. Clinical Data Interchange Standards Consortium.
8. Food and Drug Administration. PDUFA reauthorization performance goals and procedures fiscal years 2013 through 2017. 2012. Available at: http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM270412.pdf. Accessed June 27, 2013.
9. E.H. Corder, A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, G.W. Small, and et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families Science 261 1993 921 923
10. J.V. Gobburu, and L.J. Lesko Quantitative disease, drug, and trial models Annu Rev Pharmacol Toxicol 49 2009 291 301
11. Clinical Data Interchange Standards Consortium. Alzheimer's disease-specific therapeutic area supplement to the study data tabulation model user guide. Prepared by the Coalition Against Major Diseases. Jan 2014. Available at: http://www.cdisc.org/system/files/all/standard-category/application/pdf/taug-alzheimer-27s-20v2.0-20noportfolio.pdf. Accessed February 11, 2015.
12. OpenCDISC. OpenCDISC Validator. Available at: http://www.opencdisc.org/. Accessed February 11, 2015.
13. U.S. Department of Health and Human Services. Guidance regarding methods of de-identification of protected health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA) privacy rule. Available at: http://www.hhs.gov/ocr/privacy/hipaa/understanding/coveredentities/De-identification/guidance.html. Accessed February 11, 2015.
14. J.A. Rogers, D. Polhamus, W.R. Gillespie, K. Ito, K. Romero, R. Qiu, and et al. Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a beta regression meta-analysis J Pharmacokinet Pharmacodyn 39 2012 479 498
15. Food and Drug Administration. Regulatory letter to critical path institute and CAMD regarding Alzheimer's disease simulation tool. FDA Center for Drug Evaluation and Research, Disease specific model library. Available at: http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm180485.htm. Accessed February 11, 2015.
16. European Medicines Agency. Qualification opinion of a novel data driven model of disease progression and trial evaluation in mild and moderate Alzheimer's disease. 2013. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2013/10/WC500151309.pdf. Accessed February 11, 2015.
17. K. Ito, B. Corrigan, K. Romero, R. Anziano, J. Neville, D. Stephenson, and et al. Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database J Alzheimers Dis 37 2013 173 183
18. Food and Drug Administration. Janus Clinical Trials Repository (CTR) Project 2012 [6/27/13]. Available at: http://www.fda.gov/ForIndustry/DataStandards/StudyDataStandards/ucm155327.htm. Accessed February 11, 2015.
19. R.A. Rudick, N. Larocca, and L.D. Hudson Multiple Sclerosis Outcome Assessments Consortium: genesis and initial project plan Mult Scler 20 2013 12 17
20. R Project for Statistical Computing. Available at: http://www.r-project.org/. Accessed February 11, 2015.
21. Alzheimer's Association. Global Alzheimer's Association Interactive Network 2013. Available at: http://www.gaain.org/. Accessed February 11, 2015.
22. R. Jones, D. Wilkinson, O.L. Lopez, J. Cummings, G. Waldemar, R. Zhang, and et al. Collaborative research between academia and industry using a large clinical trial database: a case study in Alzheimer's disease Trials 12 2011 233
23. D.L. Beekly, E.M. Ramos, W.W. Lee, W.D. Deitrich, M.E. Jacka, J. Wu, and et al. The National Alzheimer's Coordinating Center (NACC) database: the uniform data set Alzheimer Dis Assoc Disord 21 2007 249 258
24. CAMD. C-Path online data repository. Available at: https://codr.c-path.org. Accessed February 11, 2015.
25. K. Ito, S. Ahadieh, B. Corrigan, J. French, T. Fullerton, T. Tensfeldt, and et al. Disease progression meta-analysis model in Alzheimer's disease Alzheimers Dement 6 2010 39 53
26. P.K. Panegyres, H.Y. Chen the Coalition against Major Diseases Early-onset Alzheimer's disease: a global cross-sectional analysis Eur J Neurol 2014 Apr 30 10.1111/ene.12453 [Epub ahead of print]. 2014
27. B. Szalkai, V.K. Grolmusz, V.I. Grolmusz Coalition Against Major Diseases Identifying combinatorial biomarkers by association rule mining in the CAMD Alzheimer's database 2013 Cornell University Library Available at: http://arxiv.org/abs/1312.1876 Accessed February 11, 2015
28. A. Khan, C. Yavorsky, G. DiClemente, M. Opler, S. Liechti, B. Rothman, and et al. Reliability of the Alzheimer's disease assessment scale (ADAS-Cog) in longitudinal studies Curr Alzheimer Res 10 2013 952 963
29. P.K. Panegyres, and H.Y. Chen Differences between early and late onset Alzheimer's disease Am J Neurodegener Dis 2 2013 300 306
30. S. Ueckert, E.L. Plan, K. Ito, I. Karlsson, B. Corrigan, and A.C. Hooker Improved utilization of ADAS-Cog assessment data through item response theory based pharmacometric modeling Pharm Res 31 2014 2152 2165 [Epub ahead of print]
31. S. Ueckert, E.L. Plan, K. Ito, M.O. Karlsson, B. Corrigan, and A.C. Hooker Application of item response theory to ADAS-cog scores modelling in Alzheimer's disease 2012 Population Approach Group in Europe Venice, Italy 21
32. C. Yavorsky, G. DiClemente, M. Opler, A. Khan, S. Jovic, and B. Rothman Establishing threshold scores and profiles of cognitive impairment for the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) for patients with higher dementia (MMSE < 12), Alzheimer's disease and probably MCI Alzheimers Dement 8 2012 P415 P416
33. A. Khan, C. Yavorsky, M. Opler, and S. Jovic Differential item functioning and the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) among people with Alzheimer's disease Alzheimer Dement 9 2013 P460 461
34. H.G. Eichler, F. Petavy, F. Pignatti, and G. Rasi Access to patient-level trial data-a boon to drug developers N Engl J Med 369 2013 1577 1579